Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LTG-321

Small molecule · Inhibitor of NaV1.8 sodium channel (SCN10A) · developed by Latigo Biotherapeutics

Phase 1 Most advanced trial
LTGO Developer
1 Registered trials

What is LTG-321?

LTG-321 is an orally bioavailable small molecule that inhibits the NaV1.8 sodium channel, being developed as a non-opioid analgesic.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
NaV1.8 sodium channel (SCN10A)
Mechanism
Inhibitor of NaV1.8 sodium channel (SCN10A)
Developer
Latigo Biotherapeutics (LTGO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07915947 Phase 1 PK Drug-drug Interaction Study Not yet recruiting LTGO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

PK Drug-drug Interaction Study

Other drugs acting on SCN10A

More from Latigo Biotherapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the LTGO page.

Follow LTGO, the company behind LTG-321

See LTGO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LTGO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.